ライフサイエンスコーパス: interferon-alpha

1 ion is increased in human cells treated with interferon alpha.

2 on, a defect that was completely reversed by interferon-alpha.

3 n a model using the prototypic SLE cytokine, interferon-alpha.

4 s but did not increase in those treated with interferon-alpha (0.58%).

5 MDM2, both alone and combined with pegylated interferon alpha 2a (Peg-IFNalpha 2a), significantly dec

6 f the NLEM decided to include both pegylated interferon alpha 2a and alpha 2b into the NLEM for treat

7 mparing between the combination of pegylated interferon alpha 2a or alpha 2b and ribavirin with a usu

8 , this research determined whether pegylated interferon alpha 2a or alpha 2b plus ribavirin is more c

9 HCV treatment with pegylated interferon alpha 2a or alpha 2b plus ribavirin was domin

10 Pegylated interferon alpha 2a, alpha 2b and ribavirin have been in

11 ort the three-dimensional structure of human interferon alpha-2A (IFN-alpha2A) bound to the Fab fragm

12 of subtenon injections of natural leukocyte interferon alpha-2a (IFNalpha) on best corrected visual

13 Pegylated interferon alpha-2a (PEG-IFN-alpha-2a) has previously be

14 ith vaniprevir in combination with pegylated interferon alpha-2a (Peg-IFN-alpha-2a) plus ribavirin (R

15 Children treated with pegylated interferon alpha-2a (Peg-IFN-alpha2a) +/- ribavirin in t

16 ducted a short-course (4 weeks) of pegylated interferon alpha-2a (Peg-IFN-alpha2a) plus ribavirin (RB

17 ce-daily (BID) in combination with pegylated interferon alpha-2a (Peg-IFNalpha-2a)/ribavirin (RBV).

18 All patients received pegylated interferon alpha-2a (Peg-IFNalpha-2a; 40 kD)/ribavirin (

19 ties of TG4040 in combination with pegylated interferon alpha-2a and ribavirin (PEG-IFNalpha/RBV) in

20 e safety and efficacy of simeprevir with peg-interferon alpha-2a and ribavirin (PR) in a randomized,

21 LCH and ECD improved in response to interferon alpha-2a treatment in only 50% of patients (8

22 After 4 weeks of pegylated interferon-alpha-2a/ribavirin (PEGIFN/RBV) lead-in, pati

23 ferent antiviral therapy regimens (pegylated interferon alpha 2b and ribavirin different dosages, and

24 are the cost associated with surgical versus interferon-alpha 2b (IFNalpha2b) treatment for ocular su

25 consecutively with topical MMC (0.4 mg/mL), interferon alpha-2b (1 million units/mL), or both for OS

26 f Escherichia coli-derived recombinant human interferon alpha-2b (rhIFN alpha-2b), generated by postt

27 Topical MMC and interferon alpha-2b are an effective treatment method fo

28 ficacy and safety of pretransplant pegylated interferon alpha-2b plus ribavirin (Peg-IFN-alpha2b/RBV)

29 ed and constant plasma levels of leuprolide, interferon alpha-2b, letrozole, Y-27632, octreotide, and

30 ither bevacizumab (10 mg/kg every 2 wk) with interferon-alpha (3-9 million IU 3 times/wk) (n = 11) or

31 Finally, treatment of thyroid cells with interferon alpha, a known trigger of AITD, increased TG

32 depression in the context of treatment with interferon-alpha, a widely used model to mimic depressio

33 ll eight cases assayed showed elevated serum interferon alpha activity, and gene expression profiling

34 Serum interferon-alpha activity at baseline was significantly

35 nd multiple myeloma) and 9 treatment agents (interferon-alpha, alemtuzumab, bendamustine, bortezomib,

36 d to normal by combined loss of PHF6 and the interferon alpha and beta receptor subunit 1.

37 by proinflammatory cytokines, which include interferon alpha and gamma and interleukin 2, 2R, 6, 7,

38 t days 3 and 6, compared with baseline, were interferon alpha and gamma response genes.

39 Interferon alpha and nucleos(t)ide analogues are 2 class

40 te HCV treated with 24-48 weeks of pegylated interferon alpha and ribavirin, 15 failed to achieve a s

41 ients under various treatment protocols with interferon alpha and/or nucleoside or nucleotide analogs

42 ular endothelial cells confers an ability of interferon-alpha and a soluble IL-6 receptor/IL-6 (sIL-6

43 -67 of more than 5%, previous treatment with interferon-alpha and chemotherapy, presence of diabetes,

44 f type 1 cytokines and chemokines, including interferon-alpha and CXCL10.

45 phalitis virus NS1s in the blood of infected interferon-alpha and gamma receptor-deficient mice (AG6)

46 g CCR5(+) monocytes/macrophages and enhanced interferon-alpha and interferon-gamma production 2 days

47 Consequently, antiviral interferon-alpha and interferon-gamma production, as wel

48 Importantly, SOCS1 coexpression inhibited interferon-alpha and interferon-gamma signaling and prot

49 Interferon-alpha and interferon-lambda production by per

50 ere capable of secreting effector cytokines, interferon-alpha and interleukin-12, respectively, in re

51 d induced the distinct stimulatory cytokines interferon-alpha and interleukin-12, respectively.

52 GS-9620 administration induced production of interferon-alpha and other cytokines and chemokines, and

53 Response to pegylated interferon-alpha and ribavirin (IFN-alpha/RBV) treatment

54 laprevir (TVR) in combination with pegylated interferon-alpha and ribavirin (P/R) for the treatment o

55 eavy alcohol use on treatment with pegylated interferon-alpha and ribavirin (P/R) in an insured house

56 HCV infection in combination with pegylated interferon-alpha and ribavirin in Japan, Canada, and USA

57 roven difficult and the regimen of pegylated interferon-alpha and ribavirin is only effective for hal

58 levels at baseline of therapy with pegylated interferon-alpha and ribavirin or before biopsy were cor

59 b infection and a null response to pegylated interferon-alpha and ribavirin who developed decompensat

60 pe 1 (TVR, 1125 mg every 12 hours, pegylated interferon-alpha and ribavirin).

61 erapy relies upon a combination of pegylated interferon-alpha and ribavirin, a poorly tolerated regim

62 s with the standard combination of pegylated interferon-alpha and ribavirin.

63 hibitors, used in combination with pegylated interferon-alpha and ribavirin; however, this is just th

64 e response involving the induction of type I interferons (alpha and beta interferons [IFN-alpha and -

65 Feedback mechanisms between interferons alpha and lambda (IFNs) may be affected by s

66 etroviral therapy, 11 received consolidation interferon-alpha, and 6 received consolidation high-dose

67 taglandin E(2), tumor necrosis factor-alpha, interferon-alpha, and albumin were examined.

68 ron-beta, 2',5'-oligoadenylate synthetase 1, interferon-alpha, and interferon-alpha-inducible protein

69 rmore, we show that HCV clearance induced by interferon-alpha based antiviral normalized the ER-stres

70 The long-term consequences of unsuccessful interferon-alpha based hepatitis C treatment on liver di

71 d findings suggest that patients who receive interferon-alpha based therapies but fail to clear the h

72 either treatment naive to or relapsed after interferon-alpha based therapy.

73 erwent liver biopsy during consideration for interferon-alpha based treatment between 1992 and 2007.

74 Current interferon alpha-based treatment of hepatitis C virus (H

75 by HIV/HCV coinfected individuals receiving interferon-alpha-based current standard of care.

76 sis, hepatic steatosis, and poor response to interferon-alpha-based therapy.

77 Stat1(-/-) mice lack a response to interferon alpha, beta, and gamma, allowing for replicat

78 Type I interferon (alpha/beta interferon [IFN-alpha/beta]) and

79 virus (MHV) induced the expression of type I interferon (alpha/beta interferon [IFN-alpha/beta]) in m

80 Type I interferon (alpha/beta interferon [IFN-alpha/beta]) stim

81 ing Ebola virus (EBOV) infection, the type I interferon alpha/beta (IFN-alpha/beta) innate immune res

82 The production of type I interferon alpha/beta (IFN-alpha/beta) is crucial to vir

83 and transcription, leading to suppression of interferon alpha/beta (IFN-alpha/beta) production.

84 signaling cascade resulting in production of interferon alpha/beta (IFN-alpha/beta), which promotes i

85 cently developed in AG129 mice (deficient in interferon alpha/beta and interferon gamma receptor sign

86 t positive correlation between host SOD1 and interferon alpha/beta messenger RNA (mRNA) levels, as we

87 ation of the IFN response through the type I interferon alpha/beta receptor (IFNAR).

88 lterations of the liver that depended on the interferon alpha/beta receptor (IFNAR1).

89 Neutralizing antibodies against interferon alpha/beta receptor 2 chain (IFNAR2) and tumo

90 present a case of complete deficiency of the Interferon alpha/beta receptor alpha chain (IFNAR1) in a

91 -regulation and lysosomal degradation of the interferon alpha/beta receptor chain 1 (IFNAR1) of the r

92 on and disease progression in CCHFV-infected interferon alpha/beta receptor knockout (IFNAR(-/-)) mic

93 red virus replication and spread in infected interferon alpha/beta receptor knockout mice via biolumi

94 action of IFN-beta with its receptor IFNAR1 (interferon alpha/beta receptor subunit 1) is vital for h

95 macrophages (BMMs) and partially restored in interferon alpha/beta receptor-deficient (IFNAR(-/-)) BM

96 etent animals or in animals deficient in the interferon alpha/beta receptor.

97 DD with increased expression of genes in the interferon alpha/beta signaling pathway.

98 ) triple knockout mice, which produce little interferon alpha/beta, and mice lacking the interferon r

99 ro-treated NSCLC cell lines, we elucidate an interferon alpha/beta-based transcriptional program with

100 ), interferon regulatory factor 3 (IRF3), or Interferon-alpha/beta receptor (IFNAR) by in vivo immort

101 ng the IFN-alphas and IFN-beta, activate the interferon-alpha/beta receptor (IFNAR) complex.

102 phosphorylation-dependent degradation of the interferon-alpha/beta receptor 1 chain of the type I int

103 and Irf7, is propagated by hepatocytes in an interferon-alpha/beta receptor-dependent manner.

104 Interferon-alpha/beta, NOTCH1 signaling pathways and pot

105 major host antiviral response by binding the interferon-alpha/beta-induced, ubiquitin-like ISG15 prot

106 on IL-18 in synergy with IL-12, IL-15 and/or interferon-alpha/beta.

107 tic cells (pDCs) are a main source of type I interferons alpha/beta (IFN-alpha/-beta).

108 lasmacytoid DCs can be stimulated to produce interferon-alpha by Cramp/DNA complexes, and we further

109 ion or treatment with ribavirin or pegylated interferon-alpha can result in viral clearance.

110 rmal and stimulated conditions using chicken interferon-alpha (chIFN-alpha) and the attenuated infect

111 ential need for cytoreductive therapies (eg, interferon-alpha, cladribine) in this setting.

112 -6, whereas pDCs account for lower levels of interferon-alpha compared to healthy subjects.

113 mic iron withdrawal as a marker of immediate interferon-alpha efficacy in HCV patients.

114 Moreover, interferon-alpha exposure, which activates dormant HSCs,

115 to arteries, as well as by reduced arterial interferon-alpha expression.

116 age disease (IIB-IV) and include bexarotene, interferon alpha, extracorporeal photopheresis, histone

117 y of plasmacytoid dendritic cells to produce interferon alpha following stimulation of Toll-like rece

118 Interferon-alpha has been exploited as a therapeutic tar

119 ata, hydroxyurea, somatostatin analogues and interferon-alpha have been modestly successful in patien

120 endritic cells (pDCs) produce high levels of interferon alpha (IFN-alpha) and express the apoptotic l

121 Interferon alpha (IFN-alpha) and IFN-beta are type I IFN

122 Combined treatment with interferon alpha (IFN-alpha) and ribavirin (RBV) can eff

123 ion has been treated with the combination of interferon alpha (IFN-alpha) and ribavirin (RBV) for ove

124 Interferon alpha (IFN-alpha) and ribavirin can induce a

125 he activation of NFkappaB, the expression of interferon alpha (IFN-alpha) and the induction of interf

126 rential induction of key cytokines including interferon alpha (IFN-alpha) and tumor necrosis factor a

127 Although all 12 subtypes of human interferon alpha (IFN-alpha) bind the same receptor, rec

128 atment and may be associated with the use of interferon alpha (IFN-alpha) but also with the primary p

129 n, the two accepted treatment modalities are interferon alpha (IFN-alpha) given subcutaneously for a

130 Interferon alpha (IFN-alpha) is an approved medication f

131 The mechanisms responsible for interferon alpha (IFN-alpha) production by plasmacytoid

132 nhance the rate and magnitude of HIV-induced interferon alpha (IFN-alpha) production.

133 The effect of immune activation on interferon alpha (IFN-alpha) therapy response is unknown

134 had been demonstrated by others and us that interferon alpha (IFN-alpha) treatment of hepatocytes in

135 pression is one of the major side effects of interferon alpha (IFN-alpha) treatment, but the molecula

136 Protein concentrations of interferon alpha (IFN-alpha), IFN-lambda, and IFN-gamma

137 dendritic cells (pDCs), a primary source of interferon alpha (IFN-alpha), provide a first line of in

138 This is not the case for pegylated interferon alpha (IFN-alpha)-induced neutropenia.

139 The interferon alpha (IFN-alpha)-inducible restriction facto

140 tu PRRSV replication-competent expression of interferon alpha (IFN-alpha).

141 ress the production of inflammatory cytokine interferon alpha (IFN-alpha).

142 in growth are noted in children treated with interferon alpha (IFN-alpha).

143 s from healthy donors after stimulation with interferon-alpha (IFN-alpha) and anti-immunoglobulin (Ig

144 We report here that although the cytokines interferon-alpha (IFN-alpha) and IFN-beta prevented the

145 proved treatment, a combination of pegylated interferon-alpha (IFN-alpha) and ribavirin, is frequentl

146 Interferon-alpha (IFN-alpha) can suppress production of

147 Interferon-alpha (IFN-alpha) exhibits its antiviral acti

148 Interferon-alpha (IFN-alpha) has direct inhibitory effec

149 e efficacy and safety of corticosteroids and interferon-alpha (IFN-alpha) in adults with such conditi

150 DCs derived from women produce markedly more interferon-alpha (IFN-alpha) in response to HIV-1-encode

151 Interferon-alpha (IFN-alpha) is a key mediator of antivi

152 ifferent viruses and can act in synergy with interferon-alpha (IFN-alpha) on hepatitis C virus (HCV)

153 ian target of rapamycin (mTOR) signaling and interferon-alpha (IFN-alpha) production by plasmacytoid

154 whether the elevated levels of HIV-1-induced interferon-alpha (IFN-alpha) production observed in fema

155 kappaB; however, thymocytes deficient in the interferon-alpha (IFN-alpha) receptor IFN-alphaR showed

156 y understood; however, a prolonged, elevated interferon-alpha (IFN-alpha) response is associated with

157 equires interferon-gamma (IFN-gamma) but not interferon-alpha (IFN-alpha) signalling.

158 develop depression within a short timeframe, interferon-alpha (IFN-alpha) treatment for chronic hepat

159 Currently, around 30% of patients receiving interferon-alpha (IFN-alpha) treatment for HCV experienc

160 A third of patients receiving Interferon-alpha (IFN-alpha) treatment for Hepatitis-C d

161 h risk for recurrence of malignant melanoma, interferon-alpha (IFN-alpha), a stimulator of innate imm

162 ally euthymic patients during treatment with interferon-alpha (IFN-alpha), assessing serum BDNF and r

163 replication during long-term treatment using interferon-alpha (IFN-alpha), IFN-lambda, and ribavirin

164 Two of its ligands, C3d and interferon-alpha (IFN-alpha), inhibited proliferation of

165 Interferon-alpha (IFN-alpha), interleukin-2 (IL-2), tumo

166 Type I interferons, particularly interferon-alpha (IFN-alpha), play a vital role in the h

167 ne, are strong predictors of the response to interferon-alpha (IFN-alpha)-based therapy.

168 ronic hepatitis C virus (HCV) infection with interferon-alpha (IFN-alpha).

169 All current therapies of hepatitis C include interferon-alpha (IFN-alpha).

170 d to the secretion of substantial amounts of interferon-alpha (IFN-alpha).

171 e deduced that AGM HSCs show lower levels of interferon-alpha (IFN-alpha)/Jak-Stat1-associated gene e

172 ulate the expression of antiviral cytokines (interferon alpha [IFN-alpha] and IFN-beta) but induced c

173 ity of intranasal treatment with human alpha interferon (alpha-IFN) to reduce lung and nasal wash tit

174 Both interferon alpha (IFNalpha) and immune complexes are pot

175 Interferon alpha (IFNalpha) has been used to treat pancr

176 Polycythemia vera (PV) treatment with interferon alpha (IFNalpha) is frequently limited by dos

177 Interferon alpha (IFNalpha) is important for antiviral a

178 Interferon alpha (IFNalpha) is widely used for treatment

179 We examined the effects of interferon alpha (IFNalpha) on the expression of human m

180 erapeutic options are available, among which interferon alpha (IFNalpha) presents interesting propert

181 ic cells (pDCs) with excessive production of interferon alpha (IFNalpha) represents one of the hallma

182 t tumor necrosis factor alpha (TNFalpha) and interferon alpha (IFNalpha) stimulate PML expression whi

183 The efficacy of interferon alpha (IFNalpha) therapy for chronic hepatiti

184 to show that HIV infection of the thymus and interferon alpha (IFNalpha) treatment alone result in MH

185 into hepatoma cells and inhibit signaling by interferon alpha (IFNalpha), but have no effect on HCV-R

186 Here, we found that interferon alpha (IFNalpha)-secreting MSCs showed more d

187 vels, lupus-associated autoantibodies, serum interferon-alpha (IFNalpha) activity, 25-hydroxyvitamin

188 production of inflammatory cytokines such as interferon-alpha (IFNalpha) and tumour necrosis factor (

189 Interferon-alpha (IFNalpha) has been implicated in the p

190 Interferon-alpha (IFNalpha) has been used to treat chron

191 Interferon-alpha (IFNalpha) has potent immunostimulatory

192 Interferon-alpha (IFNalpha) has shown promise in the tre

193 Numerous observations implicate interferon-alpha (IFNalpha) in the pathophysiology of sy

194 Interferon-alpha (IFNalpha) is a heritable risk factor f

195 Interferon-alpha (IFNalpha) is a pleomorphic cytokine pr

196 Interferon-alpha (IFNalpha) is a primary pathogenic fact

197 Interferon-alpha (IFNalpha) is an effective treatment of

198 Interferon-alpha (IFNalpha) is an important component of

199 Increased interferon-alpha (IFNalpha) levels and signatures, which

200 TLR) agonists and proteasome inhibitors, and interferon-alpha (IFNalpha) levels were measured by ELIS

201 ary monocyte-derived cells were treated with interferon-alpha (IFNalpha) or IFNalpha-inducing toll-li

202 rosine phosphatases (PTPs) in the absence of interferon-alpha (IFNalpha) response associated with ins

203 ay be exploited for the targeted delivery of interferon-alpha (IFNalpha) to elicit an appropriate res

204 ring antiviral therapy, specific delivery of interferon-alpha (IFNalpha) to infected cells may increa

205 Interferon-alpha (IFNalpha), a type I interferon, is exp

206 ps of hematopoiesis as well as the effect of interferon-alpha (IFNalpha), which may target the JAK2(V

207 s unknown, the antiosteoclastogenic cytokine interferon-alpha (IFNalpha), whose transcriptome is pres

208 Like SLE monocytes, interferon-alpha (IFNalpha)-primed control monocytes sti

209 eutics tyrosine kinase inhibitors (TKIs) and interferon-alpha (IFNalpha).

210 However, the role of interferon alpha in immune activation is a double-edged

211 bodies to NETs, and expressed high levels of interferon-alpha in diseased arteries.

212 associated with a reduced ability to induce interferon-alpha in primary human plasmacytoid dendritic

213 Bevacizumab/interferon-alpha induced a mean change in tumor SUV(max)

214 ists identify patients at risk of developing interferon-alpha-induced depression, and monitor those r

215 Interferon-alpha-induced genes were expressed at a highe

216 the (NZB x NZW)F(1) (NZB/NZW) mouse model of interferon-alpha-induced lupus nephritis and treated mic

217 owards, the identification and monitoring of interferon-alpha-induced-depression and the decision-mak

218 ighted interferon lambda 2 (IFN-lambda2) and interferon alpha-inducible protein 6 (IFI6) as genes pro

219 Here, we show that interferon alpha-inducible protein 6 (IFI6) is necessary

220 denylate synthetase 1, interferon-alpha, and interferon-alpha-inducible protein 27 messenger RNAs of

221 in-12 and interleukin-18), but was bereft of interferon-alpha inducing properties, confirming its hig

222 mary reporter gene assays were paralleled by interferon-alpha induction activities in whole human blo

223 We define a central role for type I interferons (alpha interferon [IFN-alpha] and IFN-beta)

224 proved that autoantibodies directed against interferon-alpha, interferon-beta, interleukin-1alpha (I

225 Interferon alpha is the only treatment option for hepati

226 Furthermore, HCV treatment with interferon-alpha leads to specific MAIT cell activation

227 kinase 2 (JAK2) inhibitors, or low doses of interferon-alpha led to the generation of greater number

228 numbers correlated positively with IL-10 and interferon alpha levels and fewer CD4(+) and CD8(+) T ce

229 Further, while interferon alpha levels were higher in SLE (p < 0.0001),

230 Here, we show that monocytes activated by interferon alpha, lipopolysaccharide or a combination of

231 Interferon alpha-mediated STAT1 phosphorylation was high

232 Here, we demonstrate that interferon-alpha-mediated stimulation of the immunoprote

233 suggested that these genes were involved in interferon alpha, nuclear factor-kappa B (NFkB), extrace

234 ptor enhancing the antireplication effect of interferon-alpha on hepatitis C virus (HCV).

235 ne of HCV RNA was typically slower than with interferon-alpha or protease inhibitors, and 12 patients

236 cantly longer median TTNT when compared with interferon-alpha (P = .0067), histone deacetylase inhibi

237 pe 56 polymorphisms found in 13 genes in the interferon-alpha pathway.

238 activation (patients with HCV-infection and interferon-alpha, patients with major depression, and he

239 ials investigating the efficacy of pegylated interferon alpha (PEG-IFNa) showed HDV RNA negativity ra

240 (MDM2) antagonist (RG7112) and the pegylated interferon alpha (Peg-IFNalpha 2a) to target JAK2V617F h

241 Combination treatment with pegylated-interferon-alpha (PEG IFN-alpha) and ribavirin, the curr

242 Egyptian CHC patients treated with Pegylated interferon-alpha (Peg-IFN) plus ribavirin.

243 d difficult to treat in the era of pegylated interferon-alpha (Peg-IFN-alpha) and ribavirin regimens.

244 Pegylated interferon-alpha (PEG-IFN-alpha) forms an integral part

245 The use of pegylated interferon-alpha (pegIFN-alpha) has replaced unmodified

246 Treatment with pegylated interferon alpha (PegIFNalpha) and ribavirin is still re

247 e studied the antiviral potency of pegylated interferon-alpha (pegIFNalpha) against HEV infections in

248 response (SVR) in CHC patients on pegylated interferon alpha plus ribavirin (pegIFNalpha/ribavirin)

249 The outcome of treatment with pegylated interferon alpha plus ribavirin treatment and sustained

250 be reduced to normal range with the standard interferon alpha plus ribavirin treatment.

251 roxyurea, mainly used in older patients, and interferon alpha, primarily given to younger patients.

252 erentially mobilized by plerixafor with high interferon-alpha producing ability.

253 measurable antiviral activity was related to interferon alpha production.

254 DC-expressed MyD88 promoted interferon-alpha production by plasmacytoid DCs, which w

255 not result in significantly higher levels of interferon-alpha production than the levels in mock-infe

256 cytes had impaired STAT1 phosphorylation and interferon-alpha production to CpG stimulation and a den

257 s R892W carrier responded normally to CpG by interferon-alpha production, carrier B cells showed impa

258 oid dendritic cell (pDC)-hyperactivation and interferon-alpha production.

259 We record increased interferon alpha protein levels using digital ELISA, enh

260 Microbial elements, HIV-1, and interferon alpha - putative drivers of HIV-1 associated

261 this question, we introduced a deficiency of interferon alpha receptor 1 (Ifnar1) into B6.Aec1Aec2 mi

262 P also plays an important inhibitory role in interferon-alpha receptor (IFNAR) signaling in mice.

263 1 transcription factor signaling through the interferon-alpha receptor (Ifnar1), resulting in the ant

264 icient to stabilize a similar complex of the interferon-alpha receptor and TYK2.

265 rix metalloproteinase-2 (MMP-2), MMP-13, and interferon alpha-receptors 1 and 2.

266 Aim of this study was to compare ETR to Interferon alpha (recombinant Interferon) & Ribavirin in

267 f direct acting antivirals (DAAs), pegylated interferon-alpha remains the backbone of HCV therapy.

268 mDC2 and pDC produced interferon-lambda and interferon-alpha, respectively.

269 primary stimulus with lipopolysaccharide or interferon-alpha, respectively.

270 es in patients with COVID-19 showed a strong interferon-alpha response and an overall acute inflammat

271 he haplotype (rs12979860) also affects other interferon-alpha responsive chronic viral illnesses, nam

272 on the surface of primary macrophages in an interferon-alpha-responsive manner, captures murine leuk

273 cells with TKI alone, or in combination with interferon-alpha, results in the preferential survival o

274 ort of 876 naive CHC patients, who completed Interferon alpha & Ribavirin for 24 weeks, was studied f

275 ilable therapy for HCV infection is based on interferon-alpha, ribavirin and the new direct-acting an

276 ponsiveness in treatment-naive and pegylated interferon alpha-ribavirin (P/R)-experienced subjects an

277 HCV treated with telaprevir (TVR)/pegylated-interferon alpha/ribavirin.

278 nd safety of standard-therapy with pegylated-interferon-alpha/ribavirin (Peg-IFN-alpha/RBV (48 weeks)

279 imen, with and without concomitant pegylated interferon-alpha/ribavirin therapy.

280 eported high response rates with recombinant interferon-alpha (rIFN-alpha) therapy in patients with e

281 led us to prospectively evaluate recombinant interferon-alpha (rIFNalpha) in "early" PM patients with

282 rculating mononuclear cells revealed reduced interferon-alpha secretion in response to herpes simplex

283 Interferon-alpha seems to be the best initial treatment

284 Conventional cytotoxics and interferon-alpha still have an established role in treat

285 Bevacizumab/interferon-alpha strongly decreases tumor uptake whereas

286 Interferon-alpha therapy may be an effective antiviral t

287 d hepatitis B surface antigen (HBsAg) during interferon-alpha therapy.

288 nistration of inflammatory cytokines such as interferon-alpha to otherwise non-depressed controls inc

289 rongly determines the outcome of natural and interferon-alpha treated hepatitis C virus (HCV) infecti

290 l interfering RNA-based library screening in interferon-alpha-treated cells, we sought to characteriz

291 In vivo, interferon alpha treatment increased NK cell number and

292 PFS was negatively associated with previous interferon-alpha treatment and diabetes, whereas lower O

293 d directly in the care of patients receiving interferon-alpha treatment and had at least one year exp

294 oreover, the specific activation of pDCs and interferon-alpha treatment promoted plaque growth, assoc

295 e both neuronal autoantibodies and levels of interferon alpha, two proposed causative agents in neuro

296 gated via this method include interleukin-2, interferon-alpha, ubiquitin, antibodies and several sing

297 w-density lipoprotein, whereas production of interferon-alpha was not affected.

298 Serum levels of interferon alpha were significantly lower in patients wi

299 Cladribine and interferon alpha were therapeutically the most effective

300 signaling and leading to rapid secretion of interferon-alpha, which was essential for the innate ant